

A28 cancelled.

horseradish peroxidase-conjugated goat anti-rabbit IgG (1;10000) for 30 min at room temperature. Bound antibody was visualized by chemiluminescence (ECL). The densitometry was performed with a Multi-Analyst program (Bio-Rad). To determine antibody specificity, anti-RHAMM antibodies were incubated with beads-lined with RHAM protein (1µg antibody/20 µl beads) for 1h at 4C on a Rotator, and then centrifuged for 5 min. The supernatant was used to probe membranes. --

In the Claims:

Please amend Claims 1, 2, 5, 7, 15, 19, 23, 24, 28, 29, and 33 by replacing them with the following:

A29

-- 1. (AMENDED) Polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77) and human V2 (SEQ ID NO: 78). --

-- 2. (AMENDED) A pharmaceutical composition for the treatment of an inflammatory neurological disorder comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), and human V2 (SEQ ID NO: 78). --

-- 5. (AMENDED) A pharmaceutical composition for the treatment of diabetes mellitus comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID

A30

A 30 concluded
NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ. ID NO: 77),
human V2 (SEQ ID NO: 78). --

431
-- 7. (AMENDED) An antibody which binds to a polypeptide
comprising an amino acid sequence selected from the group consisting of
P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO:
73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7
(SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO:
78), murine V3 (SEQ ID NO: 79), human V3 (SEQ ID NO: 83). --

32
-- 15. (AMENDED) A method for treating an inflammatory neurological
disorder comprising the step of administering to a patient a compound
selected from the group consisting of (a) a polypeptide comprising an
amino acid sequence selected from the group consisting of P16 (SEQ ID
NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3
(SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO:
76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78),
human V3 (SEQ ID NO: 83) and (b) an antibody to the polypeptide
of (a). --

33
-- 19. (AMENDED) A method for treating a disease selected from the
group consisting of arthritis, inflammatory dermatosis, inflammatory
bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity,
lupus, cardiovascular disease and diabetes mellitus, the method
comprising the step of administering to a patient a compound selected
from the group consisting of (a) a polypeptide comprising an amino acid
sequence selected from the group consisting P16 (SEQ ID NO: 26), P32
(SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO:
74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine

A33 concurred

V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: 83) and (b) an antibody to the polypeptide of (a). --

A34

-- 23. (AMENDED) A method for treating wounds comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: 83) and (b) an antibody to the polypeptide of (a). --

-- 24. (AMENDED) Use of polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26) P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: 83) for the treatment of an inflammatory neurological disorder. --

A35

-- 28. (AMENDED) Use of a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: 83) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus. --